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ABSTRACT: Chronic diseases - eg heart disease, cancer, diabetes, mental disorders - affect around 80% 
of older Australians, are the main causes of disability and premature death, and account for 70% of total 
health expenditures. Because lifestyle patterns are major risk factors, chronic disease prevention and 
treatment  are  not  only  of  medical  concern,  but  also  of  considerable  social,  family-level  and  personal 
interest.  While  this  makes  microsimulation  approaches  particularly  suitable  for  assessing  intervention 
costs and benefits, such approaches will need to be combined with disease-progression models if health 
status and treatment choices are also to be simulated.  AIMS: Describe methodological and technical 
proposals  for  the  development  of  a  cost-benefit  model-system.  METHODS:  Several  chronic  disease 
progression models are to be linked to an ‗Umbrella‘ microsimulation model representing the Australian 
population.  To  project  20  years  ahead,  use  of  reweighting  techniques  are  proposed  for  population 
projections,  disease-specific  predictions  and  for  health-related  projections.  The  model-system  is  to 
account  simultaneously  for  Australians‘  demographic,  socioeconomic  and  health-risk-factor 
characteristics; progression of their health status; the number of chronic diseases (comorbidities) they 
accumulate over time; health-related expenditures; and changes in quality of life. Standard methods are 
proposed to estimate costs versus benefits of simulated policy interventions and related quality of life 
improvements. KEY OUTCOME: Proposal of novel methods for modelling comorbidities  - a task rarely 
attempted, although quality of life is known to decline and health expenditures to increase well above 
what a linear addition of the effects of individual chronic diseases would predict. 
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1.  BACKGROUND 
In most high and middle income countries chronic 
diseases, such as cancer, heart disease, diabetes 
and  arthritis  are  strongly  associated  with 
morbidity,  disability  and  premature  mortality. 
Their  rapid  growth  and  by  now  epidemic 
proportions are considered to be major challenges 
for  health  policy,  as  they  account  for  a 
considerable  proportion  of  public  and  private 
health  expenditures  –  World  Health  Organisation 
(WHO)  2005a;  Begg  et  al  (2007);  Lopez  et  al 
(2006). 
 
Although  currently  Australians‘  health  is  among 
the best in the world – with one of the highest life 
expectancies at birth and at age 65 years – there 
are concerns about the future due to the country‘s 
obesity prevalence being among the worst in the 
OECD  (AIHW  2006a).  Obesity  is  a  major  risk 
factor  for  chronic  diseases  (Flegal  et  al  2005; 
AIHW  2004e),  such  as  cardiovascular  disease, 
Type2  diabetes,  high  blood  pressure,  certain 
cancers,  sleep  apnoea,  osteoarthritis, 
psychological disorders and social problems (WHO 
2000). A growing proportion of obese persons and 
the ageing of the population are likely to increase 
Australia‘s  already  high  chronic  diseases  and 
comorbidy prevalences. 
 
In  Australia,  eight  major  chronic  diseases  are 
considered  high  priority  for  policy  attention:  the 
National Health Priority Areas (NHPAs) of asthma; 
cancer; cardiovascular disease; diabetes; injuries; 
mental  health;  arthritis  and  musculoskeletal 
conditions;  and  dementia.  In  2003,  NHPAs 
accounted  for  73%  of  total  burden  of  diseases 
resulting, among 65 to 69 year olds, in a 14.7% 
loss of healthy years lived (Begg et al 2007). In 
2005  chronic  diseases  affected  80%  of  older 
Australians; accounted for 50% of all deaths; and 
were  responsible  for  70%  of  total  health 
expenditures  (AIHW  2006c).  Because  lifestyle 
patterns  –  eg  unhealthy  diets,  lack  of  physical 
activity, excess alcohol and tobacco consumption 
–  are major risk factors (Yach et al 2004), chronic 
disease prevention and treatment are not only of 
medical  concern,  but  also  of  social,  family-level 
and  personal  interest  (Seymour  2007;  Griffith 
2007; Eckersley 2004). 
 
Models  able  to  assess  the  benefits  and  costs  of 
potential  chronic  disease  interventions  are  now 
used  worldwide,  partly  because  of  increasing 
awareness  of  their  usefulness  in  priority  setting, 
and partly because the alternatives to modelling – 
such as large-scale long-term clinical trials – are 
considerably  more  costly  and  time  consuming. 
However,  there  is  little  in  the  literature  that 
considers all chronic diseases simultaneously and 
places  these  into  broad  medical,  behavioural, 
social  and  economic  contexts.  Earlier  research 
tended to focus on the medical issues associated 
with  a  single  disease,  with  a  few  recent  articles 
considering one comorbid condition as well. Rarely 
have  all  major  chronic  diseases  been  studied 
simultaneously,  although  many  share  common 
lifestyle  risk  factors.  Accounting  for  all  chronic 
diseases  is  important  because  quality  of  life  has 
been shown to decline and health expenditures to 
increase  with  comorbidities  (Walker  2007a; 
Shwartz et al 1996). 
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At  the  policy  level,  there  has  been  recent 
recognition of the need to target the prevention of 
chronic  diseases,  and  to  limit  their  negative 
economic,  workforce  participation,  productivity 
and  quality  of  life  impacts.  For  example 
improvement and management of prevention and 
care are among the stated aims of the November 
2005 Australian National Chronic Disease Strategy 
(Dowrick 2006). Also, in April 2007 the Council of 
Australian Governments allocated additional funds 
for chronic disease strategies. 
2.  AIMS 
The project aims to:  
 
  model  at  the  national  level  the  links 
between  health  risk  factors  and  chronic 
diseases, taking account of comorbidities;  
  establish  how  these  links  vary  by 
demographic and socioeconomic factors;  
  build  models  of  expenditures  relative  to 
benefits; and  
  obtain  rankings  for  prevention  and/or 
treatment  interventions  for  chronic 
diseases,  comorbidities  and/or  risk 
factors.  
 
The key aim of building such a model system is to 
improve  current  decision  making  by  providing  a 
more complete view of chronic disease costs and 
benefits  under  different  prevention  and/or 
treatment scenarios. The purpose of this paper is 
to  document  the  data  and  modelling  methods 
proposed for the project. Details are in Walker et 
al (2008). 
3.  OVERVIEW OF MODEL SYSTEM 
Building  the  model  system  requires:  (a)  the 
development  of  a  set  of  person-level 
demographic,  socioeconomic,  lifestyle  and  health 
variables at a particular point in time; and (b) the 
projection into the future of both disease-specific 
incidences  and  prevalences,  and  the  progression 
at  the  level  of  the  individual  of  chronic  diseases 
and  comorbidities.  Part  (a)  involves  the  bringing 
together,  in  a  coherent  manner,  individual-level 
cross-sectional  data  from  several  sources,  while 
Part  (b)  requires  use  of  disease-specific 
longitudinal  data  to  estimate  the  incidence  and 
progression  of  chronic  diseases.  We  propose 
modelling  (a)  and  (b)  separately,  and  then  link 
the two parts, so that the ‗big picture‘ as well as 
the  ‗detail‘  associated  with  the  tracking  of 
individuals‘  health  can  be  analysed 
simultaneously.  Policy  interventions  can  then  be 
assessed  in  terms  of  broad  population-wide 
variables (eg worse or improved obesity patterns; 
population  screening  options);  and  of  disease 





The  proposed  model-system,  HealthAgeingMod, 
has two parts: an ‗Umbrella‘ static microsimulation 
model  and  ‗Chronic  disease‘  econometric  or 
epidemiology-type  sub-models  (Figure  1).  It  is 
planned  that  initially  the  model-system  will 
account  for  only  two  chronic  diseases: 
cardiovascular disease (CVD) and diabetes (Type 
2).  Key  reasons  for  choosing  CVD  and  diabetes 
are  that:  (a)  they  are  major  contributors  to 
Australia‘s  total  burden  of  disease  (Begg  et  al 
2007);  (b)  for  people  with  diabetes  CVD  is  a 
common  complication  accounting  for  60%  of 
deaths; and (c) CVD and diabetes share common 
risk factors such as physical inactivity and obesity. 
Once the benefits of HealthAgeingMod are proven 
with these two disease-specific sub-models, then 
further  diseases  may  be  added  (eg  cancers, 
arthritis,  mental  health).  However,  an  ability  to 
simultaneously  study  CVD  and  diabetes  will 
already  be  a  significant  improvement  on  the 
traditional disease-by-disease analyses.  
 
In  Figure  1,  the  Umbrella  model‘s  base-year 
dataset  is  drawn  from  the  Australian  Bureau  of 
Statistics‘ (ABS) 2004-05 National Health Survey 
(NHS05)  –  (ABS  2006a,b,c,d).  Because  NHS05 
only  covers  private  dwellings  (ie  mainly 
households),  we  propose  to  complement  its  unit 
record dataset with the institutionalised population 
in  ABS‘s  2003  Survey  of  Disability  Ageing  and 
Carers (SDAC03) – (ABS 2005a; 2004a,b,c). The 
list  of  NHS05  demographic,  socioeconomic,  risk 
factor,  disease,  disability  and  quality  of  life 
variables selected for use in the Umbrella model 
(in  the  ‗2005‘  Box)  is  quite  comprehensive. 
However,  some  NHS05  variables  will  need  to  be 
modified  and  variables  not  in  NHS05  to  be 
imputed. 
 
We  propose  that  the  Umbrella  model  be  able  to 
project  20  years  ahead,  at  5-year  intervals  -  ie 
that, from 2005, it project for 2010, 2015, 2020 
and  2025.  The  5-year  intervals  will  allow 
simulation  of  diabetes  and  CVD  screening 
interventions  that  are  recommended  to  be 
repeated  every  five  years.  The  disease  specific 
sub-models will project ahead at yearly intervals, 
so disease specific projections that are likely to be 
needed yearly (eg onset of diseases, deaths) can 
be  stored  during  the  simulation  phase.  The 
population  projections  will  be  estimated  so  that 
the model‘s weighted base population lines up, to 
the extent possible, with published ABS population 
projections  (ABS  2005b).  Then  the  Umbrella 
Model will consult each chronic disease model to 
estimate, probabilistically, how each person‘s risk 
factor  profiles  and  chronic  disease(s)  would 
develop over the 5-year period being considered, 
and  whether  the  person  would  have  any  new 
chronic diseases. An important challenge will be to 
find appropriate ways to project the evolution of 
individual-level risk factors and comorbidities, and 
then  ensure  that  in  aggregate  these  individual-
level  time  profiles  line  up  with  published 
aggregate statistics.
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Figure 1  Chronic disease model-system   
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Running the Umbrella Model in ‗default‘ mode (ie 
no  policy  change)  will  provide  the  baseline 
simulation  (Figure  1,  ‗Base-Scenario  Outcomes‘ 
Box).  To  allow  for  the  simulation  of  policy 
interventions, a ‗Specify Scenario parameters‘ box 
will need to be added to the Umbrella model, and 
filled-in prior to Scenario simulations. The baseline 
and  scenario  results  will  then  be  compared  in 
terms  of  differences  in  health  outcomes  -  eg 
Disability  Adjusted  Life  Years  (DALYs)  avoided  - 
and in health expenditures. The Outcomes module 
will also present year-by-year net benefit and cost 
streams,  and  compute  cost  effectiveness 
indicators (eg cost/DALY avoided). 
4.  METHODOLOGY 
For both the Umbrella and the sub-models, most 
of  the  methods  proposed  are  ‗current  best 
practice‘. However, there will be challenges, such 
as:  developing  new  methods  to  model 
comorbidities;  modifying  traditional  methods  to 
accommodate  much  improved  up-coming 
datasets;  and  linking  the  elements  of 
HealthAgeingMod  so  that  both  the  disease  and 
comorbidity  details  can  be  validated  against 
published  aggregate  statistics.  The  methods 
eventually  used  will  be  documented  once 
HealthAgeingMod is built. Those proposed in this 
paper are described below.  
 
The  Umbrella  model  will  be  based  on  microdata 
(that  is  person-level  information),  and  will  make 
use  of  microsimulation  techniques.  Because 
models  based  on  microdata  deal  with  the 
individual, use of such models allows the impact of 
policy changes to be examined in far greater detail 
than is possible with more traditional approaches. 
Since the SAS programming language has proved 
to  be  particularly  suitable  for  microsimulation 
projects, we propose to use SAS for building the 
Umbrella  model,  as  well as  its  linkages  with  the 
disease-specific models.  
 
The  Umbrella  model  will  represent  the  full 
Australian population through use of the ‗weights‘ 
embedded in NHS05 (ABS 2006b). The proportion 
of  the  total  population  with  a  particular  chronic 
disease is generally small (eg 3.5% for diabetes; 
2%  for  both  angina  and  other  ischaemic  heart 
diseases  –  ABS  2006a).  Because  of  this  we 
propose  that  each  survey  individual  with  one  or 
more of the chronic diseases be transformed into 
a number of unit records, summing to the ‗weight‘ 
initially  attached  to  that  survey  individual. 
Enumeration  of  all  persons  with  the  chronic 
disease will allow a much finer specification of the 
health  variables  imputed  onto  the  Umbrella 
model‘s  base  dataset  (eg  measured  glucose 
levels) than what would be possible without such 
enumeration.    The  sub-  models  will  be  disease-
specific  incidence  and/or  progression  models, 
predicting changes over time in the health states 
and risk factors of each individual included in the 
Umbrella  model‘s  population.  Disease-specific 
models  can  be  of  varied  types:  eg  econometric, 
transition  probability,  parametric,  proportional 
hazard or Weibull models. The model-system will 
also  make  use  of  standard  cost-benefit  and  cost 
effectiveness methods (Jena and Philipson 2007). 
5.  UMBRELLA MODEL 
As noted above, the Umbrella model will be of the 
microsimulation  type.  Although  microsimulation 
was  first  proposed  in  the  1950s  (Orcutt  1957; 
Orcutt  et  al  1961),  its  general  use  had  to  wait 
until  computer  technology  improved  and  large 
microdatasets  became  routinely  available.  While 
many  full  population-based  microsimulation 
models  had  been,  or  are  being,  developed 
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security  fields  (see  review  in  Zaidi  and  Rake 
2001). The few that account for health tend to be 
either  of  the  socioeconomic  type,  which  use  a 
broad indicator of health as a covariate within the 
larger  picture,  or  of  the  disease-specific  type, 
designed  to  study  disease  specific  treatment 
options  so  as  to  assess  their  cost  effectiveness 
(see reviews in Lymer 2009 and Walker 2009). 
 
Major model building requirements include ability 
to:  (a)  account  for  comorbidities.  For  this  the 
Umbrella model will need to track individuals over 
time  –  from  the  onset  of  their  first  chronic 
disease; the contracting of their second, third etc 
chronic  diseases;  until  death.;  (b)  represent  all 
Australians,  so  that  broad  public  health  policy 
initiatives can be studied; and (c) simultaneously 
consider a wide range of social, economic, health 
and  person-level  variables.  While  many  of  these 
are  now  routinely  available  in  ABS  surveys, 
indicators  of  the  important  linkages  between 
physical  health,  mental  health  and  general 
wellbeing  are  in  general  significantly  under-
represented (Appleby 2006; Wilkinson 2005; WHO 
2005b).  These  requirements  suggest  a  dynamic 
microsimulation  model  based  on  nationally 
representative  longitudinal  unit  record  data. 
However,  in  Australia  such  datasets  tend  to  be 
cross-sectional  in  nature.  Also,  although  such 
datasets do contain a wide range of variables, the 
aggregate  nature  of  many  of  the  disease-level 
variables means that they do not fully meet our 
requirements.  Hence  we  propose  a  static 
microsimulation  Umbrella  model,  with  its  base-
year  population  projected  20  years  ahead  at  5-
year intervals.  
5.1.  Choice of data sources 
The most suitable data for the Umbrella model‘s 
base-year  population  are  the  ABS‘s  nationally 
representative  cross  sectional  Confidentialised 
Unit  Record  Files  (CURFs).  The  Bureau‘s  health 
and  disability  surveys  cover  most  variables 
relevant  to  this  project,  although  not  always  at 
the  level  of  detail  required.  The  National  Health 
Surveys  (NHSs)  only  concern  private  dwellings. 
Thus,  although  people  in  institutions  often  have 
poor  health,  the  NHSs  exclude  those  in  non-
private  dwellings  (such  as  hospitals,  hostels, 
nursing  homes).  Limited  information  on  the 
institutionalised  is  however  available  from  the 
ABS‘s  Survey  of  Disability,  Ageing  and  Carers 
(SDAC).  Because  these  surveys  are  repeated 
every  three  to  six  years,  aggregate  ‗trend‘ 
information can be obtained by studying changes 
in patterns across the cross-sectional surveys.  
 
Both the NHS05 and SDAC03 rely on self-reported 
data; use multistage sampling techniques, and are 
based on interviews with qualified ABS personnel 
in private dwellings. SDAC also has information on 
the  institutionalised  through  questionnaires  filled 
in by institution staff. The related CURFs comprise 
around 25,000 unit records for NHS05 and 40,000 
for  SDAC03,  each  with  over  1000  demographic, 
socioeconomic,  health,  etc  variables,  as  well  as 
ABS-estimated  person-level  ‗weights‘.  The 
application of weights ensures that survey-based 
population-wide  estimates  will  conform  by  age, 
sex and State to independently estimated national 
distributions.  In  NHS05,  the  disadvantages 
associated  with  self-rated  data  are  attenuated 
through  most  respondents  with  NHPA  conditions 
reporting that they had been medically diagnosed 
with these diseases (ABS 2006d).  
 
Because  the  NHSs  have  the  broadest  relevant 
variable  coverage,  the  most  recent  of  these, 
NHS05,  was  initially  selected  to  provide  the 
Umbrella  model‘s  base  population.  To  this 
population we propose to add the institutionalised 
embedded in SDAC03. Because NHS08 - expected 
to  become  available  in  late  2009  -  will  have 
additional  and  more  detailed  data,  we  plan  to 
update  the  Umbrella  model‘s  base  data  in  2009 
using the NHS08 CURF. This will allow use to be 
made of NHS08‘s new features, such as measured 
Body Mass Index (BMI) and disability status data. 
 
To  impute  more  detailed  or  ‗not  in  NHS05‘ 
variables  onto  the  Umbrella  model‘s  base-year 
dataset  we  propose  to  use  the  AusDiab 
longitudinal  database  (International  Diabetes 
Institute 2006). AusDiab is a national longitudinal 
study, with 11,247 persons surveyed in the 1999-
00  (Wave  1),  and  6,500  of  these  attending  the 
2004-05  update  (Wave  2).  Another  2000  of  the 
Wave 1 group who could not attend the up-date 
provided  survey  information.  AusDiab  has 
extensive individual-level data on diabetes, its risk 
factors  and  its  complications,  and  on  CVD.  It  is 
thus  an  excellent  source  for  validating  and 
imputing  from,  when  developing  the  Umbrella, 
Diabetes and CVD models. 
 
In  summary,  the  data  sources  initially  proposed 
for  the  Umbrella  model  are:  (a)  NHS05  (private 
dwellings)  and  SDAC03  (non-private  dwellings) 
Basic  CURFs;  (b)  NHS08  (private  dwellings)  and 
SDAC08  (non-private  dwellings)  Basic  CURFs  as 
up-dates;  (c)  AusDiab  (2000  and  2005  waves) 
and  (d)  earlier  and  current  NHS/SDAC  CURFs  to 
establish  time-trend  patterns  (eg  for  aligning 
and/or validating HealthAgeingMod).  
5.2.  Variables  chosen  for  the  Umbrella 
model 
We selected the variables shown in the literature 
as  having  a  major  impact  on  NHPA  chronic 
diseases  and  comorbidities.  We  classified  these 
into  three  groups:  (a)  not  needing  modification; 
(b)  needing  modification;  and  (c)  not  in 
NHS05/SDAC03 and thus needing imputation.  
 
(a)  Variables not needing modification 
 
The  chosen  NHS05  demographic  and  geographic 
area  variables  are:  age  (5-year  groups;  85+), 
sex,  State  and  an  area  indicator  (Major  cities, 
Inner  regions,  Other).  Although  chronic  diseases 
are  more  common  among  older  adults,  the 
Umbrella  model‘s  base  data  will  cover  all  age 
groups. This is because obesity – a key risk factor 
for  many  chronic  diseases  –  can  start  in  early 
childhood  (Baird  et  al,  2005;  Venn  et  al, 2007). 
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were  initially  identified  by  Walker  (2007a)  from 
the  NHS01  CURF.  Similar  NHS05/SDAC03 
variables are listed below. 
 
Quality of life: While there is increased interest 
in  health-related  quality  of  life  (QoL)  as  an 
indicator  of  subjective  well-being  (O‘Connor 
2004),  the  construct  of  such  indicators  poses 
methodological  difficulties  (Baumeister  2005).  In 
particular there is no consensus on whether their 
measurement  should  be  based  on  generic  or 
disease-specific approaches (O‘Connor 2004). For 
the  Umbrella  model  we  chose  the  generic 
approach  because  it  was  shown  to  be  more 
suitable for comparisons across population groups 
(Cella  and  Nowinski  2002).  That  is,  questions 
about an individual‘s overall satisfaction with life 
and  general  sense  of  personal  and  psychological 
well-being were considered more appropriate than 
any  question  mentioning  a  particular  disease  – 
O‘Connor  (2004).  In  NHS01  and  NHS05  the 
general health and quality of life question(s) were 
asked before any illness-specific questions, so as 
to  avoid  disease-specific  questions  influencing 
respondents‘  perceptions  of  their  overall  health 
and QoL.  
 
NHS05 contains only one QoL indicator, compared 
with  two  in  NHS01.  Based  on  the  findings  of 
Walker et al (2008), we propose to impute from 
NHS01  the  ‗Delighted  to  Terrible  Scale‘  variable, 
which is not available in NHS05.  
 
Health  status:  we  chose  the  NHS05  self-
assessed general health variable as the indicator 
of health status. Asked before any specific illness-
related  questions,  this  health  question  was:  ‗In 
general would you say your health is ‗Excellent‘, 
‗Very good‘, ‗Good‘, ‗Fair‘ or ‗Poor‘. This is Item 1 
of the Short Form 36 (SF36) - O‘Connor (2004); 
ABS (2003b). Although self-rated health is viewed 
by some with suspicion, the literature proved it to 
be  an  independent  predictor  of  mortality  (Idler 
and Benyamini 1997; Mossey and Shapiro 1982).  
 
Comorbidity:  Although  complex,  the  study  of 
comorbidities  is  important  because  they  have  a 
strong  negative  impact  on  quality  of  life  and  on 
health expenditures (Walker 2007a; Shwartz et al 
1996;  Mossey  and  Shapiro  1982).  We  chose  as 
the comorbidity indicator the NHS05 count of each 
survey respondent‘s major chronic illnesses. This 
count  concerns  conditions  that  respondents  had 
been told by a doctor or a nurse that they had at 
the time of the interview, and which had lasted or 
was expected to last for 6 months or more.  
 
A  disadvantage  of  the  number  of  chronic 
conditions variable is that it accounts for both life 
threatening and less serious health conditions (eg 
for  heart  disease  as  well  as  for  reduced  sight). 
Because  SDAC03  contains  information  on  the 
severity of disability, we propose to improve the 
comorbidity  indicator  by  imputing  a  ‗severity 
factor‘  from  SDAC03  onto  the  Umbrella  model‘s 
Base population.  
 
 
Socioeconomic  status:  has  been  shown  to  be 
associated  with  health  status,  comorbidities  and 
functionality  (AIHW  2002a,d;  Begg  et  al  2007). 
The  most  commonly  used  indicators  of 
socioeconomic  status  (SES)  are  the  ABS‘s 
geographic area-based Socioeconomic Indexes for 
Areas  (SEIFAs)  –  ABS  2003a.  SEIFAs  are  not 
ideal,  because  everyone  living  in  a  geographic 
area  is  allocated  the  same  SES,  and  because 
geographically based indicators have been shown 
to considerably underestimate the extent of health 
inequalities by socio-economic status (Walker and 
Becker 2005). We propose to use as the indicator 
of SES the NHS05‘s gross weekly equivalised cash 
income  quintile  variable.  While  this  variable  has 
the  usual  reliability  problem  associated  with 
survey income data, it has the advantage of being 
‗equivalised‘,  thus  reflecting  each  person‘s  living 
standard within the household. 
 
Education: is a variable associated with both SES 
and  health  (AIHW  2002d).  To  account  for 
secondary  as  well  as  tertiary  education,  we 
propose  to  construct  a  new  education  variable 
using  both  the  NHS05  ‗highest  year  of  school 
completed‘  and  ‗highest  post-school  qualification‘ 
variables.  
 
Social  support:  impacts  on  health,  since  living 
alone,  social  isolation  and  mental  health  were 
found to be correlated with social exclusion (AIHW 
2002d; Taylor et al 2004). To indicate individual-
level  differences  in  the  extent  of  social  support, 
we  propose  to  construct  a  ‗living  situation‘ 
variable, which will be 1 if the person lives alone, 
and 0 if the person lives with others.  
 
Work status: Australians in good health are more 
likely  to  have  a  job  than  those  in  poor  health 
(Walker  2007b).  Also,  chronic  illnesses  are 
associated  with  considerable  work  days  lost 
(AIHW,  2005a).  Data  on  work  status,  together 
with data on main source of personal cash income, 
could  be  used  to  construct  a  partial  indicator  of 
chronic disease severity. For example, if an older 
person  reported  a  high  number  of  chronic 
diseases,  worked  only  a  few  hours  a  week  and 
reported  government  as  his/her  main  source  of 
income, then ill heath may have had a  negative 
influence on that person‘s living standard. 
 
Tobacco:  smoking  is  a  major  risk  factor  for 
chronic  diseases  (AIHW  2002d).    We  propose  to 
construct a (0,1) variable indicating the extent of 
tobacco use from the NHS05 variables - for 18+ 
year  olds  -  of  having  never  smoked,  or  being  a 
current or past smoker.  
 
Alcohol: Excessive alcohol consumption is also an 
important  risk  factor  for  chronic  diseases  (AIHW 
2002d).  The  indicator  chosen  for  the  Umbrella 
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(b)  Variables needing modification  
 
Overweight  and  obesity:  is  considered  by  the 
World  Health  Organisation  to  have  reached 
epidemic proportions (WHO 2005a), and is known 
to  be  a  major  risk  factor  for  several  long-term 
chronic  diseases  (AIHW  2002d).  However,  the 
detail  on  overweight/obesity  in  NHS05  is 
insufficient  for  purposes  of  linking  the  Umbrella 
model  to  the  chronic  disease  sub-models.  The 
NHS05  indicator  of  overweight/obesity  for  15+ 
year  olds  is  the  Body  Mass  Index  (BMI).  It  is 
based on self-reported height and weight data and 
is grouped into three thin, two normal and three 
overweight  categories.  What  the  chronic  disease 
sub-models  need,  however,  is  continuous 
measured  values  of  BMI  at  the  level  of  the 
individual. Combined with the grouped NHS05 BMI 
information, we propose use of the AusDiab data 
to  estimate  continuous  measured  BMI  values  for 
individuals in HealthAgeingMod‘s basedata, and to 
check  these  estimates  against  NHS08  measured 
BMI benchmarks once the NHS08 CURF becomes 
available.  
 
Blood  pressure,  cholesterol  and  blood 
glucose  levels:  High  blood  pressure,  high 
cholesterol (total and LDL) and high blood glucose 
levels  are  known  risk  factors  for  several  chronic 
illnesses (ABS 2003c). The detail at which these 
variables are available in NHS05, that is whether 
‗ever told has condition by a doctor or nurse‘, is 
once again insufficient for our purposes. Combined 
with  this  broad  level  NHS05  information,  we 
propose  use  of  AusDiab  to  estimate  continuous 
measured  values  for  blood  pressure,  cholesterol 
and blood glucose levels. 
(c) Variables needing imputation 
 
Burden  of  disease:  To  measure  the  health 
benefits  arising  from  the  policy  interventions 
simulated we will need to attach, to each person 
in the Umbrella model‘s base dataset, an indicator 
of the burden of their diseases. From among the 
commonly  used  health  outcome  measures  we 
propose the Disability Adjusted Life Years (DALY) 
indicator (Hartge 2006; Steenland and Armstrong 
2006;  Lopez  et  al,  2006;  Begg  et  al  2007),  for 
which generally accepted disease burden weights 
are available. These will need to be imputed onto 
each basedata individual.  
 
Health care costs: Data on health expenditures 
will also need to be imputed. Earlier researchers 
found  that  in  the  1990s  the  costs  of  treating 
Australians with comorbidities were five times that 
of other persons (Department of Health and Aged 
Care,  2000),  and  that  the  costs  for  people  with 
multiple conditions were well above what a linear 
addition  of  the  effects  of  individual  chronic 
diseases would have predicted. We propose to use 
published health expenditure data, such as AIHW 
(2005b,c; 2006 d), Clarke et al (2007) and Wolff 
et al (2002). 
5.3.  Developing the base-year dataset 
The first step in developing the Umbrella model‘s 
base-year  dataset  involves:  (a)  extracting  the 
chosen variables from NHS05; (b) examining, for 
each  of  these  variables,  the  extent  of  ‗non-
response‘;  and  (c)  deciding  whether  the  level  of 
‗non-response‘ is acceptable. In ABS surveys the 
variables  most  likely  to  have  unacceptably  high 
levels  of  ‗non-response‘  are  the  income-based 
variables,  and  variables  concerning  certain 
diseases (eg mental illness). If the level of ‗non-
response‘ is acceptable (say less than 3-5%), then 
deleting  the  records  with  ‗non-response‘  may  be 
an option. However if too many variables require 
deletions,  then  this  would  detract  from  the 
nationally representative nature of the initial CURF 
population.  An  alternative  is  to  impute  onto 
records with ‗non-response‘ values for the related 
variables,  so  that  their  distribution  across  the 
whole population (eg by age/sex groups) does not 
affect the group averages.  
 
As  seen  earlier,  the  second  step  involves 
modification of those NHS05variables that do not 
exactly meet our purposes and the third imputing 
variables  that  are  not  in  NHS05.  For  most 
imputations  we  propose  to  use  the  Monte  Carlo 
method.  It  involves  the  drawing  of  a  random 
number,  z,  from  a  uniform  distribution  over  the 
interval [0, 1], and then comparing it to published 
targets  -  eg  the  prevalence  of  high/low  blood 
glucose  levels  by  age/sex/BMI  groupings.  If  the 
random number is below the relevant target, then 
the  person  being  processed  is  allocated  to  that 
particular blood glucose group. 
5.4.  Projecting 20 years ahead 
The  Umbrella  model‘s  projection  module  will 
estimate:  (1)  the  ‗ageing‘  of  the  model‘s  base 
population at 5-year intervals (preferably by age, 
sex and broad health status/comorbidity); (2) the 
health  state  transitions  for  each  person  in  that 
population in each time interval; and (3) the value 
of the comorbidity index for the period. Figure 2 
presents a flowchart of the projection module. 
 
For step (1) we propose the ‗reweighting‘ method, 
using  the  ABS‘s  GREGWT  optimising  software. 
Briefly,  the  optimising  ‗reweighting‘  method 
involves  changing  the  original  sample  survey 
weights,  so  that  application  of  the  new  weights 
(from  GREGWT)  reproduces  the  population 
distribution  forecast  by  ABS  (2005b)  for  the  5-
year  time  period  being  considered.  Step  (2)  will 
up-date the health states of each individual in the 
Umbrella model‘s base population by querying the 
relevant disease specific sub-models. Step (3) will 
compute health benefits (in DALYs) and track each 
individual‘s comorbidity pattern.  
 
This latter task will be particularly challenging and 
time consuming as it will require development of 
new  methods  to  adequately  account  for 
comorbidities. Extensive discussions with peers in 
Australia  and  overseas  are  planned,  particularly 
regarding  the  strengths  and  weaknesses  of 
possible  ‗comorbidity‘  options.  Another  challenge 
for the projections module will be to ensure that 
both  its  disease  and  its  comorbidity  projections 
can be validated against published official health 
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would  be  to  align  the  overall  model-generated 
disease progression and comorbidity patterns with 
external  targets.  Should  this  be  required,  there 
will probably be a need to develop an appropriate 
automated  alignment  method,  as  methods  for 
aligning  microsimulation  models  are  still  at  an 
early stage of development (Walker 2009). 
Figure 2  Umbrella model‘s Projection module 
 
 
5.5.  Cost-benefit  analysis  of  proposed 
interventions 
Cost–benefit  analysis  has  the  advantage  -  over 
cost-minimisation,  cost-effectiveness  and  cost-
utility  analyses  -  of  using  money,  a  common 
neutral measure, for both costs and benefits. The 
method  involves  computing  monetary  flows  of 
costs  and  benefits  over  time.  In  most  studies 
discounting is used to account for people‘s general 
preference  for  money  ‗in  the  hand  now‘  (rather 
than  for  money  expected  in  future).  From  the 
streams of costs (or benefits) a single measure is 
often computed in the form of net present value 
(NPV).  NPV  is  the  sum  of  the  yearly  discounted 
cash  values  over  that  period.  From  the  NPVs 
either a net gain (that is, benefits minus costs) or 
a  benefit–cost  ratio  (that  is,  benefits  divided  by 
costs) can be computed, which can then be used 
for  ranking  various  proposals.  A  disadvantage  of 
this approach is that not all costs or benefits can 
be expressed in monetary terms. However, the  
 
cost–benefit approach can be complemented with 
cost–utility  analysis  to  allow  for  consideration  of 
hard-to-measure factors such as disability-free life 
years  gained.  This  is  what  we  aim  to  achieve 
through estimation of DALYs. 
 
We  propose  that  the  Umbrella  model‘s  ‗Cost-
benefit module‘ first be run in ‗default‘ mode (ie 
no  policy  change).  This  will  provide  the  baseline 
simulation.  Next,  the  model  is  to  be  run  in 
‗Scenario‘ mode (ie with the policy change). The 
‗Cost-benefit  module‘  will  then  compare  the 
baseline and scenario health outcomes in terms of 
DALYs  avoided,  as  well  as  the  base-scenario 
differences  in  terms  of  monetary  benefits  and 
costs. The module will also present year-by-year 
net  expenditures;  compute  cost  effectiveness 
indicators  (such  as  cost/DALY  avoided);  and 
estimate  monetary  benefit  to  cost  ratios.  Once 
several scenarios had been simulated, they are to 
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cost/DALY;  benefit  to  cost  ratio).  Colagiuri  and 
Walker (2008) present an example of this process 
for  a  diabetes-specific  prevention  and  care 
intervention  scenario  using  a  dynamic-group-
simulation-model. 
6.  DISEASE-SPECIFIC SUB-MODELS 
A  number  of  models  have  been  reported  in  the 
literature  which  simulate  the  incidence  and/or 
progression  of  CVD  and  diabetes  (eg  Mui  1999; 
Clarke et al 2004; Colagiuri and Walker 2008). In 
this  project  we  aim  to  make  use  of  existing 
disease-specific models, since the challenge is to 
build a complex and validated model-system and 
not  the  development  of  disease-specific  models. 
Our chronic disease models will need to be able to 
carry  out  four  functions:  (1)  up-date  the  ‗risk 
factors‘ of the person being processed; (2) predict 
who will become ‗newly diagnosed‘ (with diabetes 
and/or CVD) within the period being considered; 
(3)  for  those  already  diagnosed,  predict  the 
progression  of  their  disease(s);  and  (4)  keep 
records  of  the  risk  factors,  health  status  and 
comorbidity status of the person being processed 
–  with  the  records  being  accessible  by  the 
Umbrella model. 
6.1.  Diabetes sub-model 
6.1.1.  Background 
In  recent  years  diabetes  was  one  of  the  most 
important contributor to Australia‘s total burden of 
diseases (Begg et al 2007) with around 3.5% of 
Australians (700,000 persons) diagnosed with the 
disease (ABS 2006a). Although Type2 diabetes is 
more  common  among  older  Australians,  it  is 
increasingly affecting younger age groups (AIHW 
2006b). Also, diabetes related health system costs 
were high at around $0.8 billion (AIHW 2004a). 
6.1.2.  The Diabetes sub-model 
We propose that the Diabetes sub-model focus on 
Type 2 diabetes. Although data on Type1 and its 
complications  will  be  recorded  in  the  Umbrella 
model‘s base dataset, we propose to model Type1 
diabetes in a considerably less complex way than 
Type2  diabetes.  For  the  latter  we  will  need 
separate incidence and progression modules. For 
those  already  diagnosed,  there  are  several 
individual-level  models  able  to  predict  the 
progression  of  Type2  diabetes.  Although  such 
models were built for different countries and use 
varied programming languages, we aim to use one 
of these as our ‗diabetes progression module‘.  
 
Incidence  module:  Because  modelling  the 
incidence of diabetes is considerably less complex 
than  modelling  its  progression,  we  propose  to 
build the incidence module in-house, making use 
of an external data source such as AusDiab. This 
is  because  between  1999-00  and  2004-05 
Australians with pre-diabetes were found to be 7-
8  times  more  likely  to  develop  diabetes  than 
people with normal blood glucose levels (Magliano 
et al 2008). 
 
Progression  module:  Earlier  diabetes  models  - 
Eastman  (1997a,b);  Institute  for  Medical 
Informatics and Biostatistics (1997a,b); Bagust et 
al  (2001);  Walker  et  al  (2003)  -  were  plagued 
with  data  limitations  and  thus  could  not  fully 
capture the clustering of the chronic diseases that 
tend  to  develop  as  complications  of  diabetes. 
These  limitations  were  attenuated  in  the  more 
recent United Kingdom Prospective Diabetes Study 
(UKPDS)  Outcomes  Model,  which  is  based  on 
longitudinal,  validated  data  comprising  3642 
persons  with  diabetes  (Clarke  et  al  2004).  It 
estimates, at the level of the individual, a set of 
Weibull and Gompertz equations which predict the 
first occurrence and timing of each of seven Type 
2  diabetes  complications:  fatal  or  non-fatal 
myocardial  infarction  (MI),  other  IHD,  stroke, 
heart  failure,  amputation,  renal  failure,  eye 
disease (measured as blindness in one eye) and 
death.  Explanatory  variables  include:  age,  sex, 
race,  smoking  status,  BMI,  history  of 
complications;  and  risk  factors.  Using  random 
effects panel data regressions, the UKPDS model 
also estimates the progression of Type 2 diabetes 
risk  factors,  and  computes  quality-adjusted  life 
expectancies. 
 
We propose  – and obtained permission to use  – 
the UKPDS Outcomes model as our Diabetes sub-
model‘s progression module (Walker et al 2008). 
Challenges  in  incorporating  this  model  into  our 
model-system  include:  the  matching  of  the 
relevant  variables  across  the  Umbrella  and  the 
UKPDS  models;  interfacing  the  two  models 
programmed in different languages; and ensuring 
that the UKPDS model provides all the diabetes-
related estimates required by the Umbrella model. 
6.2.  Cardiovascular disease sub-model 
Cardiovascular  disease  (CVD)  continues  to  be  a 
major cause of deaths (AIHW 2004f) and a major 
contributor  to  Australia‘s  total  burden  of  disease 
(Begg et al 2007). 
 
We propose to build a CVD incidence model with 
separate  equations  for  stroke  and  for  coronary 
heart disease. Earlier CVD model builders – eg Mui 
(1999)  –  used  the  Anderson  et  al  (1991) 
cardiovascular  risk  equations  and  these  are  still 
considered  to  be  appropriate  predictors  of  CVD 
incidence  in  developed  countries.  Indeed,  the 
newly  endorsed  2009  National  Health  and 
Research Council guideline recommends using this 
equation in Australia. Thus, for the CVD incidence 
model‘s ‗default‘ mode, we propose the Anderson 
et al (1991) equations (Table 1). They are based 
on 5573 initially CVD-free 30 to 74 year olds from 
the  US  Framingham  Heart  and  Framingham 
Offspring studies. The period covered was 1968 to 
1975, including 12-year follow-ups. The Anderson 
parametric statistical equations separately predict 
probabilities  for:  MI,  coronary  heart  disease 
(CHD),  CHD  death,  stroke,  CVD  and  CVD  death. 
Explanatory  variables  include  age,  sex;  systolic 
blood  pressure,  cigarette  smoking,  cholesterol 
(ratio  of  total  to  HDL)  and  diabetes.  One 
advantage  of  the  Anderson  parametric  model  - 
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that  predictions  can  be  obtained  relatively  easily 
for  different  lengths  of  time.  The  authors 
recommended  time  intervals  of  4  to  12  years. 
They concluded that, apart from stroke, the CHD 
equation  was  a  good  predictor  for  all  the  other 
conditions  modelled.  Hence  our  proposal  to  only 
use  in  our  CVD  model  the  CHD  and  stroke 
equations.  
 
Another  -  particularly  desirable  -  feature  of  the 
Anderson et al (1991) equations is that they allow 
for consideration of people who will develop CVD, 
as  well  as  people  who  have  both  diabetes  and 
CVD. Use of this feature in HealthAgeingMod will 
allow  considerable  simplification  of  the  CVD  to 
diabetes  interactions.  We  propose  to  do  this  by 
including  people  with  both  diabetes  and  CVD  in 
the  Diabetes  sub-model  only,  and  people  with 
CVD  only  in  the  CVD  sub-model.  An  unexpected 
feature of the Anderson equations is that BMI was 
found  to  be  statistically  insignificant.  However, 
certain  pre  and  post  1991  research  using 
Framingham  data  found  that  BMI  was  an 
independent  risk  factor  for  CVD  (Hubert  et  al 
1983;  Kenchaiah  et  al  2002).  Since  in  obesity-
related  simulations  of  public  health  interventions 
non-presence of BMI in the equations could result 
in benefits being significantly underestimated, we 
may on occasion need to consider alternative CVD 
equations.  In  such  instances,  the  linkages 
between  the  diabetes  and  CVD  sub-models  may 
need to be reconsidered.
Table 1  Coefficients of the Anderson CHD and stroke equation
Explanatory variables  CHD  CHD 
deaths 
Stroke  CVD 
deaths 
θ0  0.9145  2.9851  –0.4312  0.8207 
θ1  –0.2784  –0.9142  –  –0.4346 
β0  15.5305  11.2889  26.5116  –5.0385 
female  28.4441  0.2332  0.2019  0.2243 
log(age)  –1.4792  –0.9440  –2.3741  8.2370 
(log(age))
2  –  –  –  –1.2109 
log(age)* female  –14.4588  –  –  – 
(log(age))
2 * female  1.8515  –  –  – 
log (SBP)  –0.9119  –0.5880  –2.4643  –0.8383 
cigarettes (Y/N)  –0.2767  –0.1367  –0.3914  –0.1618 
log (total-C/HDL_C)  –0.7181  –0.3448  –0.0229  –0.3493 
diabetes  –0.1759  –0.0474  –0.3087  –0.0833 
diabetes * female  –0.1999  –0.2233  –0.2627  –0.2067 
ECG-LVH  –0.5865  –0.1237  –0.2355  –0.2946 
Source:  Anderson et al (1991) 
6.3.  Linkages  between  Diabetes  and  CVD 
models 
Published  statistics  indicate  that  there  are 
considerable links between the diabetes and CVD 
chronic diseases. For example, ABS (2006a) found 
that 20% of people (and 27% of 65+ year olds) 
with  diabetes  also  reported  having  a  long  term 
heart, stroke or vascular disease. Also, Barr et al 
(2007)  reported  that  over  two-thirds  of  all  CVD 
deaths  in  the  AusDiab  cohort  occurred in  people 
with diabetes or pre-diabetes. Although being able 
to apply the CVD model only to persons without 
diabetes  makes  the  linking  of  diabetes  and  CVD 
sub-models unnecessary, statistics of this kind are 
expected to be useful when validating the chronic 
disease model-system. 
 
7.  LINKING  THE  UMBRELLA  MODEL  WITH 
DISEASE-SPECIFIC SUB-MODELS 
The steps proposed for the Umbrella to Diabetes 
and CVD model linkages are as follows.  
 
Every  time  the  Projection  module  processes  an 
individual in the Umbrella model‘s population, the 
module  first  queries  whether  the  person  has 
diagnosed  diabetes.  If  yes,  then  it  obtains  risk 
factor and disease progression estimates from the 
UKPDS model and updates these in the person‘s 
Umbrella model records. If no, then the Projection 
module obtains up-dated risk factor estimates for 
people  without  diabetes,  and  uses  these  when 
querying the Diabetes incidence module.  
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If the person is found to have ‗new‘ diabetes, then 
his/her  records  are  up-dated  in  the  Umbrella 
model.  From  then  onwards,  CVD  for  this  person 
with diabetes will be assessed and progressed via 
the UKPDS model. 
 
If however the person is found not to have ‗new‘ 
diabetes, then the Projection module queries the 
CVD incidence module to determine whether the 
person has newly diagnosed fatal or non-fatal CHD 
or stroke. If yes, then the person‘s records in the 
Umbrella  model  are  updated.  If  no,  then  the 
Projection module moves on to process the next 
person in the Umbrella model‘s population. 
8.  VALIDATING THE MODEL SYSTEM 
Acceptance and use of HealthAgeingMod for policy 
relevant applications crucially depends on it being 
convincing  validated  against  publicly  available 
benchmark statistics. We propose that  validations 
be  carried  out  both  at  cross-sections  and  over 
time.  Zaidi  and  Rake  (2001)  note  that  when 
models are constructed from several sub-modules, 
there  will  be  multiple  sources  of  error  and  thus 
there will be many levels at which validation could 
occur.  They  suggest  that  in  such  cases 
consideration should be given to use of multiple-
module  validation  techniques.  Although  multiple-
module  validation  is  rarely  used,  we  propose  to 
consider  it  in  this  project  as  it  could  offer 
additional  insights  into  the  workings  of  the 
Umbrella model. 
 
As  initial  steps,  we  propose  validation  in  four 
phases once the prototype is built and had been 
aligned. This would involve: 
  comparing  the  estimates  obtained  from 
use  of  overseas  material  (ie  the  UKPDS 
model  and  the  Anderson  CVD  equations) 
with the few available and/or forthcoming 
Australian benchmarks; 
  checking  that,  once  data  transformations 
and imputations had been completed, the 
aggregate  statistics  generated  by 
HealthAgeingMod for its base year closely 
match  the  related  external  benchmarks 
(eg by the ABS and AIHW); 
  for  diabetes  and  CVD,  comparing  model 
system  projections  with  the  trends 
indicated  by  published  cross  sectional 
benchmarks  (such  as  the  NHSs).  Checks 
against external statistics are proposed for 
disease  incidence,  prevalence,  deaths, 
health  outcomes  (DALYs)  and  health 
expenditures;  
  HealthAgeingMod  outputs  from  ‗test‘ 
scenario  simulations  are  proposed  to  be 
compared with published results produced 
by  other  models  that  simulated  similar 
scenarios. 
9.  LIMITATIONS 
One limitation of our model system – as of other 
models  and  most  statistical  collections  -  is  their 
inability  to  fully  replicate  the  real  world. 
Nevertheless,  models  can  handle  considerable 
complexity and, if they contain key variables and 
their  inter-relationship,  then  model  simulations 
can prove to be very valuable to decision makers. 
We  aim  to  ensure  our  model  system‘s  policy 
usefulness by including all the variables identified 
in  the  literature  as  key  drivers  of  disease 
incidence, prevalence and health expenditures.  
 
Another  limitation  arises  from  use  of  the  Monte 
Carlo  method,  since  this  method  introduces 
randomness  into  the  model‘s  outputs.  That  is, 
different  runs  of  the  model  -  with  identical 
parameters  but  using  different  random  number 
seeds - will produce different outputs. To assess 
the importance of the related stochastic variation 
it will be necessary to execute several runs until 
the  results  ‗converge‘  within  set  bounds.  Earlier 
researchers  found  that,  with  microsimulation 
models,  the  number  of  repetitions  required  to 
achieve ‗convergence‘ was relatively small – four 
runs in Pudney and Sutherland (1993; 1994) and 
six  runs  in  Walker  et  al  (2006a,b).  A  further 
limitation  may  arise  if  attribution  of  burden  of 
disease to a particular risk factor (eg obesity) is 
required.  In  such  cases  we  will  endeavour  to 
choose the attribution method that is least likely 
to create limitations. Such a choice may however 
be  restricted  due  to  unavailability  of  appropriate 
data  (Hartge  2006;  Steeland  and  Armstrong 
2006). 
10.  POTENTIAL  POLICY  RELEVANT 
APPLICATIONS 
Possible  applications  include:  (1)  simulating  the 
impact  of  various  lifestyle  interventions  (eg 
obesity/overweight,  smoking,  alcohol 
consumption) on health outcomes and health care 
costs  associated  with  individual  chronic  diseases 
and  with  comorbidities  (diabetes  and  CVD 
initially);  (2)  comparing  such  analyses  across 
chronic  diseases  individually,  and  the  diseases 
combined  (eg  across  groups  of  2,  3,  4,  or  5+ 
illnesses).  The  aim  would  be  to  identify  key 
comorbidity  patterns  and  the  intervention  points 
most  likely  to  be  effective;  (3)  simulating  the 
impacts of various combined lifestyle and disease-
specific treatment options, and carrying out cost-
benefit  analyses  so  that  these  highly  complex 
options can be assessed and ranked. 
11.  DISCUSSION AND CONCLUSIONS 
The  proposals  in  this  paper  show  that  the  tasks 
set for the project are not only complex, but also 
require considerable creativity and innovation. Key 
novel elements are that the proposals cover both 
the broad socioeconomic and the detailed disease 
specific  aspects;  that  they  account  for  several 
chronic  diseases,  modelling  the  onset  and 
progression  of  each;  and  that  the  onset  or 
progression  of  these  diseases  depend  on  their 
often  common  risk  factors.  The  proposals  thus 
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reforms  that  can  combine  medical  treatment 
options  (eg  a  new  drug  being  used  for  diabetes 
and/or  new  hospital  procedures  for  stroke 
management) with lifestyle changing options (eg 
diet  and/or  exercise)  and  with  socioeconomic 
reform options (eg improving the health of poorer 
population groups). 
 
Another  important  novel  element  is 
HealthAgeingMod‘s  ability  to  assess  the  full 
benefits  of  interventions  that  target  risk  factors 
common to several chronic diseases. For example, 
in traditional models (Eastman et al. (1997a, b); 
Clarke et al (2004); Colagiuri and Walker (2008)), 
the  estimated  benefits  from  single-disease-
prevention  interventions  are  limited  to  that 
disease itself, even when the intervention affects a 
risk factor - such as obesity - that is common to 
several  chronic  diseases.  HealthAgeingMod  can 
simultaneously  analyse  risk  factor  interventions 
that  impact  on  multiple  chronic  diseases,  so  its 
benefit  estimates  are  more  comprehensive  than 
those  of  traditional  models.  At  the  policy  level, 
availability of such an improved model is likely to 
encourage  consideration  of  more  complex 
interventions that simultaneously target multiple-
chronic diseases.  
 
Another novel element, which is difficult to handle 
analytically and to place in a nation-wide context, 
is  the  estimation  of  the  number  of  chronic 
diseases that individuals are likely to accumulate 
as  they  age.  The  difficulty  arises  in  part  from 
national  health  data  collections  tending  to  focus 
on single diseases, and in part from the number of 
diseases  a  person  has  being  rarely  available  in 
data sources and being hard to model.  
 
During the model building phase further creativity 
and  innovation  will  be  needed  in:  (1)  data 
collection,  selection  and  linkage;  (2)  approaches 
and  methods  chosen  for  the  building  of 
HealthAgeingMod;  and  (3)  broadening  of  the 
boundaries  of  the  health  sectors  analysed  –  the 
coverage  comprising  individuals‘  lifestyles, 
individuals as patients, medical treatment options, 
and government policy initiatives in health care as 
well  as  in  prevention.  However,  our  proposals 
show that while there are constraints on what is 
achievable in the short term, already planned data 
collections  and  methodological  progress  could  in 
future  result  in  significant  improvements  in 
models such as HealthAgeingMod. 
 
In view of the above we expect that, once built, 
the  proposed  model-system  and  its  applications 
will  demonstrate  the  benefits  of  a  system-wide 
approach  to  chronic  disease  and  comorbidity 
prevention and treatment. Given the considerable 
quality of life benefits from prevention, as well as 
lesser  demand  for  doctors,  pharmaceuticals  and 
hospital  services,  an  important  goal  for 
HealthAgeingMod  applications  will  be  to  clearly 
indicate the relative merits of prevention options 




Research for this paper was carried out as part of 
an  Australian  Research  Council  grant  titled 
―Chronic Disease Prevention and Treatment: Cost-
Benefit  Model  Systems  to  Assist  with  Priority 
Setting‖ (DP0559650, 2005-2010). 
 
Since preparation of this paper the model-system 
has  been  completed  and  validated.  It  is 
documented  in  Walker  A,  Butler  J,  Colagiuri  S, 
2011,  Cost-Benefit  Model  System  of  Chronic 
Diseases  to  Assess  and  Rank  Prevention  and 
Treatment Options – HealthAgeingMod, Australian 
Centre for Economic Research on Health Research 





ABS  (Australian  Bureau  of  Statistics),  2006a, 
National Health Survey 2004-05, Summary of 
Results, Cat No 4364.0, Canberra. 
—2006b,  National  Health  Survey  2004-05, 
Confidentialised Unit Record Files. 
—2006c,  National  Health  Survey  2004-05:  CURF 
Information Paper, Cat No 4324.0 and National 
Health Survey 2004-05 Questionnaire, Cat No 
4363.0.55.002. 
—2006d,  National  Health  Survey  2004-05,  User 
Guide, Cat No 4363.0.55.001.  
—2005a  Disability  Ageing  and  Carers,  2003, 
Confidentialised  Unit  Record  Files  Information 
Paper (Reissue), Cat No 4430.0.00.001. 
—2005b,  Projections  of  the  Populations  of 
Australia: 2004-2101, Cat no 3222.0. 
—2004a,  Disability  Ageing  and  Carers,  2003, 
Confidentialised Unit Record Files. 
—2004b,  Disability  Ageing  and  Carer,  2003, 
Summary of Findings, Cat no. 4430.0.  
—2004c, Disability Ageing and Carer, 2003, User 
Guide, Cat no. 4431.0.55.001. 
—2004d,  Diabetes  in  Australia:  A  Snapshot,  Cat 
no 4820.0.55.001. 
—2003a,  Census  of  Population  and  Housing: 
Socioeconomic  Indexes  for  Areas  2001, 
Information Paper, Cat no 2039.0.  
—2003b,  National  Health  Survey  2001,  User 
Guide, Cat No 4363.0.55.001. 
—2003c,  Health  risk  factors,  Australia  2001,  Cat 
No 4812.0. 
—2002, National Health Survey 2001, Summary of 
Results, Cat No 4364.0. 
AIHW (Australian Institute of Health and Welfare), 
2006a, Australia's Health 2006, AIHW cat No. 
AUS 73, Canberra. 
——2006b,  Socioeconomic  inequalities  in 
cardiovascular  disease  in  Australia:  Current 
picture and trends since 1992, AIHW Bulletin 3, 
Canberra. 
—— 2006c, Chronic diseases and associated risk 
factors in Australia 2006. AIHW Cat No PHE 81, 
Canberra. 
—— 2006d, Health expenditure Australia 2004-05, 
Canberra. 
——  2005a,  Obesity  and  workplace  absenteeism 
among older Australians, Canberra. 
—— 2005b, Health expenditure Australia 2003-04, WALKER AND COLAGIURI Cost-Benefit Model System of Chronic Diseases in Australia   68 
Canberra. 
—— 2005c, Health system expenditure on disease 
and injury in Australia 2000-01, Canberra. 
——  2004a,  Australia's  Health  2004,  AIHW  Cat. 
No. AUS 44, Canberra. 
—— 2004b, Disability and its relationship to health 
conditions and other factors, Canberra. 
—— 2004c, The impact of dementia on the health 
and aged care systems. Canberra. 
—— 2004d, Cancer Australia 2001, Canberra. 
—— 2004e, The relationship between overweight, 
obesity  and  cardiovascular  disease,  Cat.  No. 
CVD 29, Canberra. 
—— 2004f, Heart, Stroke and Vascular Disease - 
Australian facts 2004, AIHW Cat. No. CVD 27, 
Canberra. 
——  2002a,  Older  Australians  at  a  Glance,  Third 
Edition,  AIHW  cat.  no.  AGE25,  AIHW  and 
DoHA, Canberra. 
——  2002b,  Diabetes:  Australian  Facts  2002, 
Diabetes Series No. 3 AIHW Cat. No. CVD 20, 
Canberra. 
——  2002c,  Diabetes:  Australian  Facts  2002, 
Diabetes Series No. 3 AIHW Cat. No. CVD 20, 
Canberra. 
—— 2002d, Chronic diseases and associated risk 
factors in Australia 2001, AIHW, Canberra. 
——  1998,  Health  system  costs  of  diseases  and 
injury in Australia 1993–9, AIHW Cat. No. HWE 
5, Canberra. 
Anderson  K,  Odell  P,  Wilson  P,  Kannel  W. 
Cardiovascular disease risk profiles, Am Heart 
J, 1991; 121 (1, part 2): 293-98. 
Appleby  J.  Data  briefing:  health,  wealth  and 
happiness,  Health  Services  Journal,  2006;  25 
(May): 23. 
Bagust A, Hopkinson PK,  Maier W, Currie, C,  An 
economic  model  of  the  long-term  health  care 
burden of type ii diabetes, Diabetologia 2001; 
44 (12): 2140–55. 
Baird J, Fisher D, Lucas P, Kleijnen J, Roberts H, 
Law  C,  Being  big  or  growing  fast:  systematic 
review of size and growth in infancy and later 
obesity, British Medical Journal, 2005;331:929. 
Barr E, Zimmet P, Welborn T, Jolley D, Magliano 
D, Dunstan D, Cameron A, Dwyer T, Taylor H, 
Tonkin  A,  Wong  T,  McNeil  J,  Shaw  J,  Risk  of  
Cardiovascular  and  All-Cause  Mortality  in 
Individuals  With  Diabetes  Mellitus,  Impaired 
Fasting  Glucose,  and  Impaired  Glucose 
Tolerance 
The  Australian  Diabetes,  Obesity,  and  Lifestyle 
Study  (AusDiab),  Circulation  2007; 
116(2):151-157. 
Begg S, Vos T, Barker B, Stevenson C, Stanley L, 
Lopez A. The burden of  disease and injury in 
Australia  2003,  Australian  Institute  of  Health 
and Welfare, 2007; AIHW cat. no. PHE 82. 
Baumeister H, Balke K, Härter M, Psychiatric and 
somatic comorbidities are negatively associated 
with  quality  of  life  in  physically  ill  patients. 
Journal  of  Clinical  Epidemiology,  2005; 
58(11):1090-1100.  
Cella D, Nowinski, C. Measuring quality of  life in 
chronic  illness:  the  functional  assessment  of 
chronic  illness  therapy  measurement  system. 
Arch Phys Med Rehabil 2002; 83: S10–S17 
Clarke P, Leal J, Kelman C, Smith M, Colagiuri S, 
FRACP  (Department  of    Endocrinology,  Prince 
of Wales Hospital, NSW, Australia). Estimating 
the  cost  of  complications  of  diabetes  in 
Australia using administrative health-care-data, 
2007; Value in Health (in press July/August). 
Clarke  P,  Gray  A,  Briggs  A,  Farmer  A,  Fenn  P, 
Stevens R, Matthews D, Stratton M, Holman R. 
A  model  to  estimate  the  lifetime  health 
outcomes of patients with Type 2 diabetes: the 
United  Kingdom  Prospective  Diabetes  Study 
(UKPDS)  Outcomes  Model  (UKPDS  no.  68), 
Diabetologia, 2004; 47:1747-59. 
Colagiuri, S., Walker A, Using an Economic Model 
of  Diabetes  to  Evaluate  Prevention  and  Care 
Strategies  in  Australia,  Health  Affairs  2008; 
27(1):256-268. 
Department  of  Health  and  Aged  Care,  2000, 
Insights into the utilisation of health services in 
Australia based on linked administrative data, 
Occasional Papers, New series No 9, Canberra. 
Dowrick  C,  The  Chronic  Disease  Strategy  for 
Australia, MJA 2006; 185 (2):61-62. 
Eastman R, Javitt J, Herman W, Dasbach E et al. 
Model  of  Complications  of  NIDDM  –  Model 
Construction and Assumptions.  Diabetes Care 
1997a; 20: 725-734 
—— Model of Complications of NIDDM: Analysis of 
the  Health  Benefits  and  Cost-effectiveness  of 
Treating  NIDDM  with  the  Goal  of 
Normoglycemia,  Diabetes  Care  1997b;  20: 
735-744 
Eckersley  R.  Being  better  off  but  feeling  worse: 
what‘s happening to people in Australia? New 
Community Quarterly, 2004; 2 (3): 3-7. 
Flegal KM, Graubard BI, Williamson DF, Gail MH. 
Excess  deaths  associated  with  underweight, 
overweight  and  obesity.  JAMA  2005; 
293:1861–67. 
Friers  T,  Melzer  D,  Jenkins  R,  Social  inequalities 
and  the  common  mental  disorders:  a 
systematic  review  of  the  evidence.  Social 
Psychiatry and Psychiatric Epidemiology, 2003; 
38: 229-37. 
Griffiths C, Foster G, Ramsay J, Eldridge S, Taylor 
S.  How  effective  are  expert  patient  (lay  led) 
education  programmes  for  chronic  disease?. 
BMJ 2007; 334:1254-1256.  
Gupta,  A  and  Harding,  A  (eds),   Modelling  Our 
Future:  Population  Ageing,  Health  and  Aged 
Care,  2007,  International  Symposia  in 
Economic  Theory  and  Econometrics,  North 
Holland, Amsterdam. 
Hartge  P.  Estimating  the  burden  of  disease  and 
the  benefits  of  prevention  –  commentary, 
Epidemiology, 2006; 17 (5):498-9. 
Hubert  H,  Feinleib  M,  McNamara  P,  Castelli  W. 
Obesity  as  an  independent  risk  factor  for 
cardiovascular disease: a 26- year follow-up of 
participants  in  the  Framingham  Heart  Study, 
Circulation 1983;67;968-77. 
Idler  E,  Benyamini  Y.  Self-rated  health  and 
mortality: a review of twenty-seven community 
studies. Journal of Health and Social Behaviour 
1997; 38 (1): 21-37. 
Institute  for Medical Informatics and Biostatistics 
1997a,  ACCU-SIM  2  —  An  Overview, WALKER AND COLAGIURI Cost-Benefit Model System of Chronic Diseases in Australia   69 
Switzerland. 
——  1997b,  ACCU-SIM  2  —  Help  File  Contents, 
Switzerland. 
International  Diabetes  Institute,  AusDiab  2005: 
Tracking the Accelerating Epidemic: Its Causes 
and Outcomes, 2006. The Australian Diabetes, 
Obesity and Lifestyle Study, Melbourne. 
Jena A, Philipson T. Cost-effectiveness as a price 
control, Health Affairs, 2007; 26 (3): 696-703. 
Kenchaiah  S,  Evans,  J,  Levy  D,  Wilson  P, 
Benjamin  E,  Larson  M,  Kannel  W,  Vasan  R. 
Obesity and the risk of heart failure, N Engl J 
Med, 2002; 347 (5): 305-13. 
Lopez A, Mathers C, Ezzati M, Jamison D, Murray 
C  (Eds),  Global  Burden  of  Disease  and  Risk 
Factors, 2006, World Bank, Washington. 
Lymer  S,  2009,  APPSIM  –  Modelling  Health: 
population  ageing,  health  status  and  health 
outlays,  NATSEM  Working  Paper  No  13, 
University of Canberra, Australia. 
Magliano  D,  Barr  E,  Zimmet  P,  Cameron  A, 
Dunstan  D,  Colagiuri  S,  Jolley  D,  Owen  N, 
Phillips P, Tapp R, Welborn TA, Shaw J. Glucose 
indices,  health  behaviours  and  incidence  of 
diabetes  in  Australia:  the  AusDiab  study. 
Diabetes  Care  2008.  31:267-72.  PMID: 
17989310 
Mossey J, Shapiro E. Self-rated health: a predictor 
of  mortality  among  the  elderly,  Am  J  Public 
Health 1982; 72: 800-8. 
  Mui  S-L.  Projecting  coronary  heart  disease 
incidence  and  cost  in  Australia:  Results  from 
the  Incidence  module  of  the  Cardiovascular 
Disease  Policy  Model,  Australian    and  New 
Zealand Journal of Public Health, 1999; 23 (1): 
11-19.  
O‘Connor  R.  2004,  Measuring  Quality  of  Life  in 
Health, Churchill Livingstone, Elsevier, London. 
OECD  (Organisation  for  Economic  Co-operation 
and  Development).  Policy  Implications  of 
Ageing  Populations:  Introduction  and 
Overview, 1996, OECD Working Paper no. 33, 
Paris. 
Orcutt G. A new type of socio-economic system, 
Review of Economics and Statistics, 1957; 58 
(2). 
Orcutt G., Greenberger, M., Korbel, J., Rivlin, A. 
1961,  Microanalysis  of  Socioeconomic 
Systems: A Simulation Study, Harper and Row, 
New York. 
Pudney  S,  Sutherland  H.  1993,  Statistical 
Reliability  and  Microsimulation:  the  Role  of 
Sampling,  Simulation  and  Estimation  Errors, 
Microsimulation Policy Modelling Unit paper No 
MU 9402, University of Cambridge, UK. 
 ——  1994,  ‗How  reliable  are  microsimulation 
estimates?  An  investigation  of  the  role  of 
sampling  error  in  a  UK  tax-benefit  model‘, 
Journal of Public Economics.  
Seymour  L.  Health,  wealth  and  the  pursuit  of 
happiness, Journal of the Royal Society for the 
Promotion of Health; 2007; 127: 2. 
Shwartz M, Iezzoni L, Moskowitz M, Ash A, Sawitz 
E,  The  importance  of  comorbidities  in 
explaining differences in patient costs, Medical 
Care, 1996; 34(8):767-82. 
Steenland  K,  Armstrong  B,  An  overview  of 
methods for calculating the burden of disease 
due  to  specific  risk  factors,  Epidemiology, 
2006; 17 (5):512-9. 
Taylor,  M.,  Berthoud,  R.  and  Jenkins,  S.  2004, 
Low  Income  and  Multiple  Disadvantage: 
Analysis of the British Household Panel Survey, 
SEU, London. 
Venn A, Thomson R, Schmidt M, Cleland V, Curry 
B, Gennat H, Dwyer T. Overweight and obesity 
from  childhood  to  adulthood:  a  follow-up  of 
participants  in  the  1985 Australian  Schools 
Health and Fitness Survey, Medical Journal of 
Australia, 2007; 186 (9): 458-460. 
Walker  A,  2009,  Modelling  the  socioeconomic 
status  to  health  link  in  Australia:  A  dynamic 
microsimulation  approach,  LAP  Lambert 
Academic Publishing, Koln, Germany. 
——2007a, Multiple chronic diseases and quality of 
life:  patterns  emerging  from  a  large  national 
sample, Australia, Chronic Illness 2007: 3(3): 
202-218. 
——  2007b,  How  do  health,  socio-economic 
status, education and family connections affect 
labour  force  status?,  Australian  Journal  of 
Labour Economics (under review). 
Walker A, Butler J, Colagiuri S. 2008, Cost-Benefit 
Model System of Chronic Diseases in Australia: 
to Assess and Rank Prevention and Treatment 
Options  -  Proposed  Approach,  Australian 
Centre  for  Economic  Research  on  Health 
Research  Report  No  3,  Australian  National 
University  - 
www.acerh.edu.au/publications/ACERH_RR3.pd
f 
  Walker  A.,  Pearse  J.,  Thurecht,  Harding  A.  
Hospital Admissions by Socioeconomic Status: 
Does  the  ‗Inverse  Care  Law‘  Apply  to  Older 
Australians?‘,  Australian    and  New  Zealand 
Journal of Public Health, 2006a; 30 (5): 467-
73.  
Walker, A., Thurecht, L. and Harding, A, ‗Changes 
in hospitalisation rates and costs - New South 
Wales,  1996-97  and  2000-01‘,  Australian 
Economic Review, 2006b; 39 (4): 391-408. 
Walker  A,  Becker  N.    ‗Health  Inequalities  Across 
Socioeconomic  Groups:  Comparing 
Geographic-Area-Based  and  Individual-Based 
Indicators‘,  Public  Health,  2005;  119  (12): 
1057-1150. 
Walker, A., Colagiuri, S and McLennan, M. 2003, 
Cost–Benefit Model of Diabetes Prevention and 
Care:  Model  Construction,  Assumptions  and 
Validation,  Technical  Paper  No  28,  National 
Centre  for  Social  and  Economic  Modelling, 
University of Canberra. 
Wilkinson  R.  The  impact  of  inequality:  how  to 
make  sick  societies  healthier.  London: 
Routledge 2005. 
Wolff J, Starfield B and Anderson G, Prevalence, 
Expenditures,  and  Complications  of  Multiple 
Chronic  Conditions  in  the  Elderly,  Arch  Intern 
Med. 2002;162 (20): 2269-2276. 
World  Health  Organisation(WHO)  2005a, 
Preventing  chronic  diseases:  a  vital 
investment, Geneva. 
—— 2005b, Mental Health Atlas, Geneva. 
—— 2000, Global strategy for the prevention and WALKER AND COLAGIURI Cost-Benefit Model System of Chronic Diseases in Australia   70 
control  of  non-communicable  diseases, 
Geneva. 
Yach  D,  Hawkes  C,  Gould  CL,  et  al.  The  Global 
Burden  of  Chronic  Diseases:  Overcoming 
Impediments to Prevention and Control, JAMA 
2004; 291 (21):2616-2622. 
Zaidi,  A  and    Rake,  K  2001,  Dynamic 
Microsimulation  Models:  a  Review  and  Some 
Lessons  for  SAGE,  Discussion  paper  No  2, 
ESRC-Sage Research Group, London. 